DK1689721T3 - Aminopyrazolderivater som GSK-3-ihibitorer - Google Patents
Aminopyrazolderivater som GSK-3-ihibitorerInfo
- Publication number
- DK1689721T3 DK1689721T3 DK04798878.7T DK04798878T DK1689721T3 DK 1689721 T3 DK1689721 T3 DK 1689721T3 DK 04798878 T DK04798878 T DK 04798878T DK 1689721 T3 DK1689721 T3 DK 1689721T3
- Authority
- DK
- Denmark
- Prior art keywords
- gsk
- inhibitors
- prodrugs
- stereoisomers
- aminopyrazole derivatives
- Prior art date
Links
- JVVRJMXHNUAPHW-UHFFFAOYSA-N 1h-pyrazol-5-amine Chemical class NC=1C=CNN=1 JVVRJMXHNUAPHW-UHFFFAOYSA-N 0.000 title 1
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 title 1
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 201000004384 Alopecia Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000024963 hair loss Diseases 0.000 abstract 1
- 230000003676 hair loss Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Ceramic Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Structural Engineering (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52543603P | 2003-11-26 | 2003-11-26 | |
| PCT/IB2004/003749 WO2005051919A1 (en) | 2003-11-26 | 2004-11-15 | Aminopyrazole derivatives as gsk-3 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1689721T3 true DK1689721T3 (da) | 2010-09-20 |
Family
ID=34632981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK04798878.7T DK1689721T3 (da) | 2003-11-26 | 2004-11-15 | Aminopyrazolderivater som GSK-3-ihibitorer |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7671072B2 (da) |
| EP (1) | EP1689721B1 (da) |
| JP (1) | JP4864719B2 (da) |
| AT (1) | ATE473967T1 (da) |
| BR (1) | BRPI0416989A (da) |
| CA (1) | CA2547283C (da) |
| DE (1) | DE602004028150D1 (da) |
| DK (1) | DK1689721T3 (da) |
| ES (1) | ES2347152T3 (da) |
| WO (1) | WO2005051919A1 (da) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005075435A1 (en) * | 2004-01-30 | 2005-08-18 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス，インコーポレイティド | ムスカリン性受容体調節による神経発生 |
| US7985756B2 (en) | 2005-10-21 | 2011-07-26 | Braincells Inc. | Modulation of neurogenesis by PDE inhibition |
| WO2007053596A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| WO2007134136A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US20090318430A1 (en) * | 2006-07-21 | 2009-12-24 | Astex Therapeutics Limited | Medical use of cyclin dependent kinases inhibitors |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| KR100832747B1 (ko) * | 2006-10-27 | 2008-05-27 | 한국화학연구원 | 아미노피라졸 유도체, 이의 제조 방법 및 이를 함유하는허혈성 질환의 예방 또는 치료용 조성물 |
| US7737149B2 (en) | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
| WO2009017453A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958 |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| US10273219B2 (en) | 2009-11-12 | 2019-04-30 | Pharmatrophix, Inc. | Crystalline forms of neurotrophin mimetic compounds and their salts |
| CN102740856B (zh) | 2009-11-12 | 2015-02-18 | 特罗菲克斯制药股份有限公司 | 神经营养蛋白模拟化合物及其盐的晶型 |
| WO2011066544A2 (en) | 2009-11-30 | 2011-06-03 | Pharmatrophix, Inc. | Deuterated compounds useful for treating neurodegenerative diseases |
| WO2012006276A1 (en) * | 2010-07-06 | 2012-01-12 | North Carolina State University | Inhibition of bacterial biofilms with aryl carbamates |
| US9125408B2 (en) | 2010-09-01 | 2015-09-08 | North Carolina State University | Use of aryl carbamates in agriculture and other plant-related areas |
| WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| US20140179712A1 (en) | 2012-12-21 | 2014-06-26 | Astrazeneca Ab | Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide |
| US20170165230A1 (en) | 2014-04-09 | 2017-06-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
| CN109651171A (zh) * | 2019-01-13 | 2019-04-19 | 苏州鹏旭医药科技有限公司 | 依拉戈利及其钠盐的中间体及其盐的制备方法和应用 |
| MX2021009276A (es) * | 2019-01-31 | 2021-08-24 | Pfizer | Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibidora sobre cdk2. |
| JP2022020583A (ja) * | 2020-07-20 | 2022-02-01 | ファイザー・インク | 併用療法 |
| WO2022135442A1 (zh) * | 2020-12-22 | 2022-06-30 | 上海拓界生物医药科技有限公司 | Cdk2抑制剂及其制备方法 |
| WO2022135365A1 (en) * | 2020-12-22 | 2022-06-30 | Anrui Biomedical Technology (Guangzhou) Co., Ltd. | Disubstituted cyclopentane kinase inhibitors |
| TW202246255A (zh) * | 2021-02-12 | 2022-12-01 | 美商傳達治療有限公司 | Ｃｄｋ抑制劑及其使用方法 |
| TW202317564A (zh) * | 2021-07-01 | 2023-05-01 | 大陸商上海拓界生物醫藥科技有限公司 | Cdk2抑制劑及其製備方法和用途 |
| WO2023083201A1 (zh) * | 2021-11-09 | 2023-05-19 | 上海拓界生物医药科技有限公司 | 一种氨基吡唑衍生物及其制备方法和用途 |
| US20250195475A1 (en) * | 2022-01-27 | 2025-06-19 | InventisBio Co., Ltd. | Cdk2 inhibitor and preparation method and use thereof |
| WO2023239629A1 (en) * | 2022-06-06 | 2023-12-14 | Plexium, Inc. | Compounds and pharmaceutical compositions that degrade cdk2 |
| WO2024035830A1 (en) * | 2022-08-11 | 2024-02-15 | Relay Therapeutics, Inc. | Solid forms of a cdk inhibitor |
| CN119790039A (zh) * | 2022-09-30 | 2025-04-08 | 楚浦创制（武汉）医药科技有限公司 | 氘代吡唑类衍生物、药物组合物及应用与制备方法 |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE759838A (fr) | 1969-12-04 | 1971-06-03 | Wellcome Found | Cetones a activite biologique |
| US3885046A (en) | 1969-12-04 | 1975-05-20 | Burroughs Wellcome Co | Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression |
| GB1422263A (en) | 1973-01-30 | 1976-01-21 | Ferrosan As | 4-phenyl-piperidine compounds |
| US4314081A (en) | 1974-01-10 | 1982-02-02 | Eli Lilly And Company | Arloxyphenylpropylamines |
| NL7503310A (nl) | 1975-03-20 | 1976-09-22 | Philips Nv | Verbindingen met antidepressieve werking. |
| US4536518A (en) | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
| US4338317A (en) | 1981-03-16 | 1982-07-06 | Mead Johnson & Company | Phenoxyethyl-1,2,4,-triazol-3-one antidepressants |
| US4423049A (en) | 1981-12-28 | 1983-12-27 | Mead Johnson & Company | 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines |
| FR2534580A1 (fr) | 1982-10-13 | 1984-04-20 | Synthelabo | Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent |
| US4535186A (en) | 1983-04-19 | 1985-08-13 | American Home Products Corporation | 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives |
| NZ209876A (en) | 1983-10-17 | 1988-03-30 | Duphar Int Res | Piperazines and pharmaceutical compositions |
| IL74497A (en) | 1985-03-05 | 1990-02-09 | Proterra Ag | Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives |
| US4804663A (en) | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
| FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| DE68916980T2 (de) * | 1988-02-03 | 1994-11-17 | Nippon Steel Corp | Verfahren zum Herstellen kornorientierter Elektrostahlbleche mit hoher Flussdichte. |
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| WO1990005525A1 (en) | 1988-11-23 | 1990-05-31 | Pfizer Inc. | Quinuclidine derivatives as substance p antagonists |
| MX19222A (es) | 1989-01-23 | 1993-12-01 | Pfizer | Agentes ansioliticos bis-aza-biciclicos |
| US5272160A (en) | 1989-05-17 | 1993-12-21 | Pfizer Inc | 2-piperidino-1-alkanol derivatives as antiischemic agents |
| WO1990014087A1 (en) | 1989-05-17 | 1990-11-29 | Pfizer Inc. | 2-piperidino-1-alkanol derivatives as antiischemic agents |
| US5332817A (en) | 1990-01-04 | 1994-07-26 | Pfizer Inc. | 3-aminopiperidine derivatives and related nitrogen containing heterocycles |
| US5232929A (en) | 1990-11-28 | 1993-08-03 | Pfizer Inc. | 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use |
| RU2099339C1 (ru) | 1990-02-06 | 1997-12-20 | Пфайзер Инк. | Производные пиперидина |
| US5229382A (en) | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| US5750542A (en) | 1993-09-28 | 1998-05-12 | Pfizer | Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors |
| US5716965A (en) | 1991-05-22 | 1998-02-10 | Pfizer Inc. | Substituted 3-aminoquinuclidines |
| CA2102179C (en) | 1991-05-31 | 1998-10-27 | Fumitaka Ito | Quinuclidine derivatives |
| HU224443B1 (hu) | 1991-06-20 | 2005-09-28 | Pfizer Inc. | Fluor-alkoxi-benzaldehid-származékok |
| US5530161A (en) | 1991-07-08 | 1996-06-25 | British Bio-Technology Limited | Hydroxamic acid based collagenase inhibitors |
| GB9119932D0 (en) | 1991-09-18 | 1991-10-30 | Glaxo Group Ltd | Chemical compounds |
| DK0533268T3 (da) | 1991-09-18 | 2001-12-03 | Glaxo Group Ltd | Benzanilidderivater som 5HT-1D antagonister |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993016185A2 (en) | 1992-02-06 | 1993-08-19 | Creative Biomolecules, Inc. | Biosynthetic binding protein for cancer marker |
| GB9208492D0 (en) | 1992-04-16 | 1992-06-03 | Glaxo Spa | Heterocyclic compounds |
| US5719147A (en) | 1992-06-29 | 1998-02-17 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
| US5312925A (en) | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
| US5886009A (en) | 1992-11-12 | 1999-03-23 | Pfizer Inc. | Quinuclidine derivative as a substance P antagonist |
| US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| US5506242A (en) | 1993-01-06 | 1996-04-09 | Ciba-Geigy Corporation | Arylsufonamido-substituted hydroxamic acids |
| US5552419A (en) | 1993-01-06 | 1996-09-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| ATE201403T1 (de) | 1993-03-16 | 2001-06-15 | Pfizer | Naphtalinderivate |
| US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
| IS4208A (is) | 1993-09-22 | 1995-03-23 | Glaxo Group Limited | 3-(tetrazólýl-benzyl)amínó-piperadidín afleiður |
| JP3351065B2 (ja) | 1993-10-29 | 2002-11-25 | 日本メクトロン株式会社 | ２，２−ジフェニルヘキサフルオロプロパン類の製造法 |
| US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| EP0741724B1 (en) | 1994-01-31 | 1999-08-11 | Pfizer Inc. | Neuroprotective chroman compounds |
| MX9701282A (es) | 1994-08-18 | 1997-05-31 | Pfizer | Fenoles neuroprotectores. |
| US5633272A (en) | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| JP3053222B2 (ja) | 1995-04-20 | 2000-06-19 | ファイザー・インコーポレーテッド | Ｍｍｐおよびｔｎｆ抑制剤としてのアリールスルホニルヒドロキサム酸誘導体 |
| FR2734484B1 (fr) | 1995-05-24 | 1997-06-27 | Pasteur Merieux Serums Vacc | Composition vaccinale liquide et procede de fabrication |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| US5565483A (en) | 1995-06-07 | 1996-10-15 | Bristol-Myers Squibb Company | 3-substituted oxindole derivatives as potassium channel modulators |
| GB9520822D0 (en) | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
| ATE225343T1 (de) | 1995-12-20 | 2002-10-15 | Hoffmann La Roche | Matrix-metalloprotease inhibitoren |
| ZA9610738B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | Subtype selective nmda receptor ligands and the use thereof |
| ZA9610736B (en) | 1995-12-22 | 1997-06-27 | Warner Lambert Co | 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists |
| ZA9610741B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
| ZA9610745B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
| AU1463997A (en) | 1995-12-22 | 1997-07-17 | Acea Pharmaceuticals, Inc. | Subtype-selective nmda receptor ligands and the use thereof |
| ES2169355T3 (es) | 1996-03-05 | 2002-07-01 | Astrazeneca Ab | Derivados de 4-anilinoquinazolina. |
| US5994351A (en) | 1998-07-27 | 1999-11-30 | Pfizer Inc. | Arylsulfonylamino hydroxamic acid derivatives |
| BR9708171A (pt) | 1996-03-08 | 1999-07-27 | Hoffmann La Roche | Uso de derivados de 4-fenil-3,6-di-hidro-2h-piridila como bloqueadores de subtipo de receptor nmda |
| CN1128788C (zh) | 1996-03-29 | 2003-11-26 | 辉瑞大药厂 | 苄基(亚苄基)－内酰胺衍生物,它们的制备以及作为5－ht1a和/或5－ht1d受体的选择性拮抗剂(激动剂)的用途 |
| DE69716916T2 (de) | 1996-07-13 | 2003-07-03 | Glaxo Group Ltd., Greenford | Kondensierte heterozyklische verbindungen als protein kinase inhibitoren |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| EA199900021A1 (ru) | 1996-07-13 | 1999-08-26 | Глаксо, Груп Лимитед | Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы |
| CA2260898C (en) | 1996-07-18 | 2002-05-14 | Pfizer Limited | Phosphinate based inhibitors of matrix metalloproteases |
| UA56185C2 (uk) | 1996-09-30 | 2003-05-15 | Пфайзер Інк. | Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування |
| US6423708B1 (en) | 1996-09-30 | 2002-07-23 | Pfizer Inc | Aralkyl and aralkylidene heterocyclic lactams and imides |
| US5843504A (en) * | 1996-10-15 | 1998-12-01 | Townsend Engineering Company | Method and apparatus for coagulating the outer surface of a sausage strand discharged from a sausage extruding machine |
| DE69730151T2 (de) | 1997-01-06 | 2005-08-04 | Pfizer Inc. | Cyclische sulfonderivate |
| AU721748B2 (en) | 1997-02-03 | 2000-07-13 | Pfizer Products Inc. | Arylsulfonylamino hydroxamic acid derivatives |
| US6235741B1 (en) | 1997-05-30 | 2001-05-22 | Merck & Co., Inc. | Angiogenesis inhibitors |
| US6051593A (en) | 1997-06-20 | 2000-04-18 | Sugen, Inc. | 3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors |
| US6114371A (en) | 1997-06-20 | 2000-09-05 | Sugen, Inc. | 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors |
| ATE368665T1 (de) | 1997-08-22 | 2007-08-15 | Astrazeneca Ab | Oxindolylchinazolinderivate als angiogenesehemmer |
| DE59802413D1 (de) | 1997-09-24 | 2002-01-24 | Infineon Technologies Ag | o-Amino(thio)phenol-carbonsäuren und deren Herstellung |
| US6162804A (en) | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6133305A (en) | 1997-09-26 | 2000-10-17 | Sugen, Inc. | 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity |
| US6380203B1 (en) | 1998-01-14 | 2002-04-30 | Merck & Co., Inc. | Angiogenesis inhibitors |
| GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
| IL139934A0 (en) | 1998-05-29 | 2002-02-10 | Sugen Inc | Pyrrole substituted 2-indolinone derivatives and pharmaceutical compositions containing the same |
| NZ523656A (en) * | 2000-08-31 | 2004-11-26 | Pfizer Prod Inc | Pyrazole derivatives and their use as protein kinase inhibitors |
-
2004
- 2004-11-15 US US10/580,615 patent/US7671072B2/en not_active Expired - Fee Related
- 2004-11-15 BR BRPI0416989-1A patent/BRPI0416989A/pt not_active Application Discontinuation
- 2004-11-15 EP EP04798878A patent/EP1689721B1/en not_active Expired - Lifetime
- 2004-11-15 ES ES04798878T patent/ES2347152T3/es not_active Expired - Lifetime
- 2004-11-15 DK DK04798878.7T patent/DK1689721T3/da active
- 2004-11-15 AT AT04798878T patent/ATE473967T1/de not_active IP Right Cessation
- 2004-11-15 WO PCT/IB2004/003749 patent/WO2005051919A1/en not_active Ceased
- 2004-11-15 JP JP2006540648A patent/JP4864719B2/ja not_active Expired - Fee Related
- 2004-11-15 CA CA2547283A patent/CA2547283C/en not_active Expired - Fee Related
- 2004-11-15 DE DE602004028150T patent/DE602004028150D1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0416989A (pt) | 2007-02-06 |
| US7671072B2 (en) | 2010-03-02 |
| US20070276010A1 (en) | 2007-11-29 |
| WO2005051919A1 (en) | 2005-06-09 |
| EP1689721B1 (en) | 2010-07-14 |
| EP1689721A1 (en) | 2006-08-16 |
| DE602004028150D1 (de) | 2010-08-26 |
| ES2347152T3 (es) | 2010-10-26 |
| CA2547283C (en) | 2010-11-09 |
| JP4864719B2 (ja) | 2012-02-01 |
| ATE473967T1 (de) | 2010-07-15 |
| JP2007512315A (ja) | 2007-05-17 |
| CA2547283A1 (en) | 2005-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE473967T1 (de) | Aminopyrazolderivate als gsk-3-inhibitoren | |
| DK1641454T3 (da) | Pyrazolo[3,4-B]pyridin-6-oner som GSK-3-hæmmere | |
| EA200901373A1 (ru) | Аминогетероциклические соединения | |
| EA200401114A3 (ru) | Замещённые гидроксиэтиламины | |
| TW200728305A (en) | Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease | |
| JO2282B1 (en) | Oxazole derivatives | |
| DE602004008098D1 (de) | Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren | |
| SE0402735D0 (sv) | Novel compounds | |
| WO2007022380A3 (en) | Bis-aryl amide compounds and methods of use | |
| ATE403428T1 (de) | Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren | |
| SG170101A1 (en) | 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. | |
| MXPA05010293A (es) | 4-amino[1,2,4]triazolo[4,3-a]quinoxalinas sustituidas. | |
| WO2006044497A3 (en) | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease | |
| UY30426A1 (es) | Derivados sustituidos del 3-(4-metoxi-fenil)-3h-isoindol-1-ilamina trifluoroacetado, sus sales o solvatos farmaceuticamente aceptables, formulaciones farmacéuticas y aplicaciones. | |
| EA200900152A1 (ru) | Ингибиторы пирролотриазинкиназы | |
| EA200600223A1 (ru) | Замещённый 2-аминотетралины для лечения депрессии | |
| UA83691C2 (ru) | Применение замещенных 2-аминотетралинов для упреждающего лечения болезни паркинсона | |
| UA92181C2 (ru) | Производные пиримидина и их применение в терапии и в производстве лекарственного средства для предотвращения и/или лечения болезни альцгеймера | |
| NO20085271L (no) | Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni | |
| ATE371724T1 (de) | Behandlung neurodegenerativer krankheiten | |
| EP1817312A4 (en) | MACROCYCLIC AMINIOPYRIDYL BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER | |
| WO2006055434A3 (en) | Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease | |
| NO20064982L (no) | 1,3,4-oksadiazol-2-oner som PPAR delta modulatorer og anvendelse derav | |
| WO2008036316A3 (en) | Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease | |
| TW200716152A (en) | Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture |